Please login to the form below
Crohn's Disease
This page shows the latest Crohn's Disease news and features for those working in and with pharma, biotech and healthcare.
European approval for Skyrizi, hot on the heels of US
The analysis showed that 56% of patients on risankizumab were symptom-free after a year’s treatment, compared to 30% of the Stelara group. ... The drug is already in trials for psoriatic arthritis, Crohn's disease and ulcerative colitis.
Latest news
-
Gilead and Galapagos close in on filing for Xeljanz rival
In FINCH 1, selective JAK1 inhibitor filgotinib was compared to AbbVie’s $18bn-a-year TNF antibody Humira (adalimumab) or placebo – given on top of generic disease-modifying antirheumatic drug (DMARD) ... RA and the rest from other diseases such as
-
Celgene hopes for second time lucky for ozanimod FDA filing
The mistake was seen as a huge own goal by Celgene, and further undermined already shaky investor confidence in the company's leadership. ... Ozanimod is an oral, sphingosine 1-phosphate (S1P) receptor modulator, and is also being developed to treat
-
Takeda’s Entyvio tops Humira in ulcerative colitis
That compared to 22.5% of the arm who received Humira every other week, according to the results, which were resented over the weekend at the European Crohn’s and Colitis ... Sales of Entyvio for UC and Crohn’s disease rose around a third to $550m in
-
Boehringer’s IL-36-targeting drug tackles rare form of psoriasis
Jan Poth. For Boehringer, the successful study in GPP bodes well for BI 655130’s potential in other immune diseases, including more common indications including inflammatory bowel disease. ... Trials of BI 655130 are also underway in palmoplantar
-
AbbVie and Boehringer’s psoriasis drug Skyrizi gets CHMP nod
Johnson’s Stelara (targeting IL-23 and IL-12) and AbbVie’s own ageing market leader Humira. ... Risankizumab is also being in clinical trials for a number of other inflammatory diseases, including Crohn's disease, ulcerative colitis, atopic
More from news
Approximately 18 fully matching, plus 143 partially matching documents found.
Latest Intelligence
-
Drug launches to watch in 2019
The first test of this will be Shire’s new blockbuster-in-waiting Takhzyro, which gained EMA approval in November, for the rare disease hereditary angioedema (HAE). ... Boehringer Ingelheim) for psoriatic arthritis, Crohn’s disease and other
-
Deal Watch October 2018
Collaboration for. development. $760m. Enterome/. Takeda. EB8018 for Crohn’s disease and other gastrointestinal. ... Roche has an existing agreement with Ionis for IONIS‐HTTRx, an antisense drug for Huntington’s Disease, and the new deal is to
-
Innovation in merger control and the impact on the pharmaceutical sector
Pipeline problems. The Commission’s novel approach has its roots in pharma mergers. ... Specifically, Hospira was selling Inflectra, an infliximab biosimilar used to treat several chronic inflammatory diseases, notably the inflammation of Crohn’s
-
Deal Watch January 2018
for local administration for the treatment of complex perianal fistulas in patients with Crohn’s disease. The companies were already partners having signed a $432m licensing deal in July 2016 for ... Option exercise (2 options). 640. TiGenix/Takeda.
-
The good, the bad and the ugly
Tecfidera (MS) and Spinraza (Spinal Muscular Atrophy) are expected to generate big sales, while Tysabril (MS and Crohn’s Disease) and Avonex (MS) are expected to see sales drop due to ... However, there is a movement towards greater research in this
More from intelligence
Approximately 0 fully matching, plus 22 partially matching documents found.
Latest appointments
-
TiGenix appoints Dr Marie Paule Richard
in phase III trials for complex perianal fistulas in Crohn's disease.
-
Ex J&J VP joins board of Immune
Immune will benefit from Durrant's knowledged of the iundstry gained during time in roles such as worldwide VP at Johnson &Johnson and VP, Pharmacia until its acquisition by Pfizer. ... Its lead product candidate is bertilimumab, which is in clinical
-
Former Novartis president joins Qu Biologics
His senior industry experience will support Qu Biologics' plans to advance the development of its investigational immunotherapies for treatments such as Crohn's disease. ... Bob Pelzer's wealth of leadership experience with Novartis and DuPont will be
More from appointments
Approximately 1 fully matching, plus 2 partially matching documents found.
Latest from PMHub
-
The Real & The Honestly Fake
If the audience’s attention span has decreased, agencies and advertisers must grab what little attention there is. ... about how to deal with Duchenne, the depictions of dragons to represent the struggles of suffering with Crohn’s disease, the
-
emotive adds to medical team with new Scientific Lead and Associate Medical Writer
Kate is experienced in a wide range of therapy areas, including immunology, specifically Crohn’s disease, ulcerative colitis and psoriatic arthritis, in ophthalmology, including retinal diseases, glaucoma and dry eye disease, ... in rare
-
THE OTHER SIDE OF… CROHN’S DISEASE
Meet Irene. Like millions of others worldwide (and an estimated 115, 000 in the UK), Irene suffers from Crohn’s disease, an autoimmune disorder that causes inflammation in the gut and ... So she turns elsewhere for information. She speaks to other
-
Creativity in a complex landscape: a pharma perspective
For example, when developing messaging, it’s important to know what restrictions and barriers might come into play for different countries. ... An example of what I would consider an outstanding creative campaign is the ‘Rewrite Their Stories’
-
A safe place to talk about Crohn’s
Published in eyeforpharma April 2017 by Mariel Metcalfe. Anxiety and embarrassment are a vicious circle for people with Crohn’s disease.
More from PMHub
Approximately 5 fully matching, plus 8 partially matching documents found.
Featured jobs
-
Senior Medical Writer
-
Salary TBC
- Medical Writer/ Senior Medical Writer opportunities – Macclesfie...
-
competitive salary and benefits package
Subscribe to our email news alerts
PMHub
Blue Latitude Health
Blue Latitude Health is a creative marketing consultancy. Founded in 2003, our combination of heritage, approach and capability gives us...
Latest intelligence
- My MS journey: one patient's search for innovation
- David Lazarus charts his journey from initial MS diagnosis in 1990 to his experience participating in innovative clinical trials, along with his advice for other patients....
- Biotech profile: Tom Evans, CEO, Vaccitech.
- Can UK company be first to develop a universal flu vaccine?...
- The social dilemma: is it time for pharma to join the party?
- Chris Ross explores why social media still isn’t trending for pharma, and how it can join in the fun...
Quick links
Infographics
